Jaguar Health Inc. (JAGX) stock surged by 5.88% at the last trading close while the JAGX stock price rises by 11.11% at the last check in the pre-market trading. Jaguar Health, Inc. is a commercial-stage pharmaceutical company focusing on developing new, plant-based, non-opioid, and sustainably derived prescription drugs for people and animals suffering from gastrointestinal discomfort, especially chronic, crippling diarrhea. Napo Pharmaceuticals, Inc., the fully owned subsidiary, is focused on creating and commercializing patented plant-based human gastrointestinal pharmaceuticals derived from plants safely obtained from rainforest areas.
Jaguar Health sent a reminder today about the Innovators with Jane King interview with Lisa Conte, JAGX’s founder, president, and CEO, and Josh Mailman, the lead sponsor of the Dragon special purpose acquisition company (the “Dragon SPAC”), which will show during a webcast this Friday, April 23, 2021, to include a business analysis of Napo EU S.p.A. which is Jaguar’s wholly-owned subsidiary.
Recent Past Development
JAGX announced on April 15, 2021, that the at-the-market (“ATM”) financing program that Jaguar Health established with Ladenburg Thalmann & Co. on October 5, 2020, has been increased by $15.3 million for any future funding requirements. JAGX filed a registration statement and prospectus supplement on April 9, 2021, in accordance with its previously announced At “The Market Offering Agreement” with Ladenburg, as an agent, to increase the size of the at-the-market offering under which JAGX can offer and sell shares of Jaguar Health’s common stock from time to time via Ladenburg.
Lisa Conte, Jaguar’s president and CEO commented:
JAGX is ecstatic to have increased the ATM program’s potential. While Jaguar Health does not intend to issue any shares at this time, the upsized ATM system is intended to provide JAGX with future funding, if required, at the current market price at the time of sale, thus potentially priced at-the-market, or above-the-market, as defined by NASDAQ, based on timing.